Prospective Evaluation of Single‐Time‐Point Methotrexate Monitoring During High‐Dose Therapy in Pediatric Leukemias and Lymphomas
Pediatric Blood & Cancer · 2026
DOI: 10.1002/1545-5017.70672 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Aamir Dogra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Haematology Oncology Unit, Department of Paediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Methotrexate, Antimetabolites, Antineoplastic, Drug Monitoring. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Conventional multi‐time point monitoring during high‐dose methotrexate (HD‐MTX) therapy is often impractical in low‐ and middle‐income countries (LMICs). A simplified single‐time‐point monitoring strategy may offer a feasible alternative.
Objectives
To determine the proportion of patients achieving adequate MTX clearance (≤0.4 µmol/L) at 48 h following initiation of HD‐MTX. Methodology In this prospective observational study, children with high‐risk B‐lineage and T‐cell acute lymphoblastic leukemia receiving HD‐MTX were enrolled. Single time point MTX levels were measured 48 h from initiation of infusion. MTX level >0.4 µmol/L received intensified hydration and leucovorin rescue. Toxicities were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Patients with pre‐existing renal insufficiency or prior Grades 3 and 4 MTX toxicity were excluded.
Results
Thirty‐two children (age 2–12 years) undergoing 106 cycles of HD‐MTX were evaluated. MTX clearance at 48 h was achieved in 74.5% (79/106). Delayed clearance normalized at 72 h in 5/16 retested cycles. Age >7 years ( p = 0.025) and higher baseline serum creatinine ( p = 0.022) predicted delayed clearance. Elevated 48‐h levels correlated with neutropenia (13%, p = 0.0096), transaminitis, mucositis, and acute kidney injury occurred in 10.4%, 7.5%, and 3.8% of cycles.
Conclusions
A single 48‐h MTX level can facilitate discharge decisions in approximately 75% of treatment cycles in a preselected cohort of patients. This approach may provide a pragmatic and cost‐effective strategy in resource‐limited settings, though its safety in unselected populations remains to be established. Validation in larger, unselected cohorts is needed before broad implementation can be recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Paediatric Haematology Oncology Unit, Department of Paediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
ORCID-Profile: Prateek Bhatia, Deepak Bansal, Amita Trehan
Zitieren
APA
Dogra, A., Bhatia, P., Bansal, D., & Trehan, A. (2026). Prospective Evaluation of Single‐Time‐Point Methotrexate Monitoring During High‐Dose Therapy in Pediatric Leukemias and Lymphomas. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70672
Vancouver
Dogra A, Bhatia P, Bansal D, Trehan A. Prospective Evaluation of Single‐Time‐Point Methotrexate Monitoring During High‐Dose Therapy in Pediatric Leukemias and Lymphomas. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70672
BibTeX
@article{Dogra2026,
author = {Dogra, Aamir and Bhatia, Prateek and Bansal, Deepak and Trehan, Amita},
title = {Prospective Evaluation of Single‐Time‐Point Methotrexate Monitoring During High‐Dose Therapy in Pediatric Leukemias and Lymphomas},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70672}
}
EUVIMED